Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Lung Neoplasms 22Carcinoma, Non-Small-Cell Lung 15Ovarian Neoplasms 12Fallopian Tube Neoplasms 11Carcinoma, Hepatocellular 9Colorectal Neoplasms 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Mycosis Fungoides 5Leukemia, Lymphocytic, Chronic, B-Cell 5Carcinoma, Renal Cell 5Squamous Cell Carcinoma of Head and Neck 4Neoplasm Metastasis 4Lymphoma, T-Cell, Cutaneous 4Glioblastoma 4Colonic Neoplasms 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Sezary Syndrome 3Rectal Neoplasms 3Nasopharyngeal Carcinoma 3Multiple Myeloma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Lymphoma, B-Cell 3Endometrial Neoplasms 3Cholangiocarcinoma 3

Interventions

HDAC-42 2Bevacizumab 2temsirolimus 1neratinib 1brigatinib 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Doxycycline 1Disulfides 1Crizotinib 1Cetuximab 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 2 × Disulfides × 1 year × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡